Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that Dr Christina Coughlin, Chief Executive Officer, and Michelle Morrow, Chief Scientific Officer, will be presenting at a webinar on 15 May 2025 at 6.00 pm (BST).
The webinar is open to all existing and potential investors and will focus on the Company’s recent data presentations on its proprietary pre|CISION® candidates FAP-Dox (AVA6000) and FAP-EXd (AVA6103) at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, USA.
The Company welcomes investor interaction so there will be a Q&A session after the presentation and questions can be submitted pre-event as part of the registration process. The webinar will be hosted by Turner Pope Investments
Investors can register for the event by using the following link: